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Abstract 
Human microbiota aredistinctcommunities of microorganisms that resides at different body 
niches. Exploration of the human microbiome has become a reality due to the availability of 
powerful metagenomics and metatranscriptomic analysis technologies. Recent advances in 
sequencing and bioinformatics over the past decade help providea deep insight into the nature of 
the host-microbial interactions and identification of potential deriver genes and pathways 
associated with human health, well-being, and predisposition to different diseases.  
In the present review, we outline recent studies devoted to elucidate the possible link between the 
microbiota and various type of diseases. The present review also highlights the potential 
utilization of microbiota as a potential therapeutic option to treat a wide array of human diseases. 
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Introduction 
Humans are viewed as composites of human and microbial cells. Human microbiotaare complex 
and dynamic microbial communitiescomposed mainly ofbacteria, but also includes protozoa, 
archaea, viruses, and fungi that resides in and on different body niches such as oral cavity, throat, 
esophagus, stomach, colon, urogenital tract, respiratory tract, and skin1. The number of microbial 
cells inhabiting human body is estimated to exceed the H.sapiens cells by 10-fold  and estimated 
at 350 trillion microbial cells2. The colonic microbiota constitutes the most abundant microbial 
domain within the human body with the vast majority belonging to bacterial phyla; Firmicutes 
and Bacteroidetes3. The collective genomes of the complete human microbiota located at the 
different body sitesare referred to as human microbiome4.  Metagenome and metatranscriptome 
refers to the study of collective genes and RNA derived from a specific microbiome respectively. 
The term virome is used to describe the viral components (bacterial, archeal, eukaryotic virome, 
and virus-derived elements) while mycobiome refers to fungal organisms within human 
microbiota5-8. As shown in figure (1), the human microbiome is composed of complex 
communities of viral (virome), bacterial (microbiota) and fungal (mycobiota) and their 
associated genetic material.  The interplay among human microbiome and host cells affects 
human health and contribute in the pathogenesis of various diseases.  
Marked differences in the abundance and diversity of microbiota are observed in healthy human 
individuals along with the presence of a strong niche specialization both within and among 
individuals9. These difference may be explained due to a number of factors including differences 
in host genetics, feeding habits, life style, and early life microbial exposure10-12. Moreover, 
changes in the composition of human microbiota have profound impacts on health and may 
predispose to different immunological and pathological conditions9,13,14. These microbial 
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communities have a profound impact on human health and well-being, and each person's 
microbiome is thought to be unique. Differences in the microbiome composition can help explain 
why some people are more susceptible or resistant to certain diseases.  
Exploration of the human microbiome has recently become possible due to the availability of 
powerful metagenomics and metatranscriptomic analysis protocols. Using these protocols, it 
become possible to have a better insight on the nature of the host-microbial interactions, and to 
identify potential deriver genes, and pathways associated with human health and diseases.  
This review highlights the recent advances in human microbiome and explores possible uses of 
different microbial genetic signaturesin identifying possible disease risks. The exploration of 
novel therapeutic targets to improve human health, well-being, and to treat various diseases 
associated with microbiome dysbiosis are also mentioned. 
Role of human microbiome in health 
Accumulating evidence reveals that the gut microbiota plays a major role in promoting health, as 
a result of which it is often referred to as the ‛forgotten organ’15.  The relationship between the 
host and microbiota is symbiotic and mutualistic, each deriving benefits from the other. These 
two terms are similar but mutualism is defined as ‛an interaction between species that is 
beneficial to both of them’ and symbiosis as ‛the living together of two organisms in close 
association’16. While the host provides the microbiota with a protected and nutrient-rich 
environment, the microbiota enhance, e.g., digestion, immunity and neuronal development. 
Microbiota are key to maintaining homeostasis where it confers many benefits for the host such 
as pathogen displacement, development of the immune system, vitamin production and 
absorption of nutrients17.  The influence of microbiota on health extends beyond the GI tract 
affecting almost every organ of the body18,19.  In the intestine, microbiota affect angiogenesis20 
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and improve gut immunity and motility, as well as decreasing the permeability of the intestinal 
barrier. In distant organ such as the lungs, microbiota regulate immunological defense against 
viral infection21. Microbiota also influence behavior by reducing synaptic connectively and 
elevating anxiety22,19 and perception of pain23. In the liver, microbiota modulate hepatic 
metabolism in such a way as to decrease energy expenditure and promote adiposity24. In 
addition, absence of gut microbiota leads to more bone mass in association with fewer 
osteoclasts surface area of bone25.  Recent studies also showed that microbiota are involved in 
the development of personalized medicine26, in xenobiotic metabolism27 and in regulating blood-
tissue barriers28-30. 
Human microbiome and diseases (Dysbiosis) 
Alterations in the composition of microbiota can result from exposure to various environmental 
factors such as diet, xenobiotics, drugs, and pathogens as shown in figure (2), which eventually 
contribute to the pathogenesis of various metabolic, neurological, immunological, and cancer 
promoting diseases. The collective microbiota of the gut whose DNA contributes to the 
metagenome have links with inflammatory bowel disease (IBD), liver disorders, ankylosing 
spondylitis, neurodegenerative diseases, obesity and associated noncommunicable diseases 
(NCDs) including diabetes mellitus, hypertension, atherosclerosis, coronary heart disease, and 
neurodegenerative diseases beside other condition31-35. 
IntestinalDiseases 
Due to the direct contact between the intestine and microbiota, it is predictable that alteration in 
the composition of microbiota could be involved in the pathogenesis of many intestinal disease 
such asCrohn’s disease (CD) and ulcerative colitis (figure 3). 
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In CD, metagenomic analysis revealed a decrease in Firmicutes, in particular F. prausnitzii, and 
an increase in Enterobacteriaceae, especially the virulent invasive E. coli36. Alteration of gut 
microbiotamay affect mucosal health and immune system by acting on the epithelial barrier 
function, and regulation of the innate immune system37.Reduction in the number of F. prausnitzii 
is associated with an increasing risk for the recurrence of ileal CD 38, another study confirmed an 
increase in the number of  F. prausnitziiin pediatric CD 39. Ott and colleagues demonstrated that 
CD was associated with altered fungal profile with a marked increase in the diversity of fungal 
community.In pediatric inflammatory bowel disease (IBD), dominance of Basidiomycotaspecies 
was recorded 40.  
Viruses associated with gut bacteria may affect the pathogenesis of CD and disease-specific 
viromes had been related to CD and ulcerative colitis (UC)41.  Previous studies demonstrated a 
significant increase of Caudovirales bacteriophages concomitant with a reduction in the relative 
abundance of bacterial species, indicating a possible involvement of virome in bacterial 
dysbiosis associated with CD and UC42.  
Alterations in the homeostasis of gut microbiota may induce low-grade intestinal inflammation 
associated with irritable bowel syndrome (IBS)43,44. IBS was associated with an increase in the 
numbers of Ruminococcus, Clostridium, and Dorea, with a marked reduction in Bifidobacterium 
and Faecalibacterium spp.45. In comparison to normal population, an increase in the Firmicutes 
to Bacteroidetes ratio was evident in patients with IBS46. Dysbiosis of the gut microbiota is 
thought to play a crucial role in the development of mucosal lesions47and intestinal inflammation 
is generally believed to be associated with a specific reduction in the Bacteroidetes and 
Firmicutes phyla specially reductions in the Clostridium leptum and Clostridium coccoides 
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groups48. All of the aforementioned studies have certainly outlined a link between the gut 
microbiota and IBD. 
Association between colorectal cancer (CRC) and the presence of specific causative organism 
has been suggested. For instance, the presence of  high numbers of Fusobacterium in the gut 
microbiota has been linked to CRC49,50. Interestingly, members of Fusobacterium has been 
associated with IBS51. The initiation of chronic inflammatory condition due to dysbiosis of gut 
microbiota lead to impairment of intestinal barrier, induction of inflammation through a host 
immune response, and in turn, increase in tumor growth52.   
E. coli had been implicated in the initiation of CRC through polyketide synthase (pks) and mice 
mutants lacking the pks island had a decreased tumor growth and invasion compared to their 
wild-type pks+ counterparts49. Although there were strong correlations between inflammation 
induced by the presence of specific types of microorganisms and CRC, it was clear that further 
investigations were required to further explore the role of bacterial induced inflammation in 
tumorigenesis and CDC. 
Gastric diseases 
Although gastric pH, peristalsis and mucus layer play an essential protective role in preventing 
bacterial colonization in the stomach, maintenance of gastric microbiota homeostasis is essential 
for the stomach health. Five major phyla have been detected in the stomach including 
Bacteroidites, Actinobacteria, Fusobacteria and Proteobacteria. Healthy human stomach is 
dominated by Prevotella, Streptococcus,Veillonella, Rothia,and Haemophilus; however, the 
composition of the gastric microbiota is dynamic and is affected by diet, drugs, and diseases53.  
Sequencing of the small subunit 16S rRNA revealed that Helicobacter pylori was the 
predominant phylotype in the stomach of chronic gastritis patients54.  The interaction between H. 
This article is protected by copyright. All rights reserved 
pylori and other species within the gut microbiota might increase the risk of gastric cancer. Other 
bacterial genera such as Streptococcus, Prevotella, Neisseria, Haemophilus and Porphyromonas 
may also contribute to the development of gastritis. In this regard, the high number of 
Streptococcus genus was associated with antral gastritis 55. 
Modifications of gastric microbiota have been associated with gastric cancer or precancerous 
conditions. Although gastric cancer is known to be a multifactorial disease, H. pylori infection 
was found to actively contribute to its progression, probably by induction of chronic atrophic 
gastritis leading to reduction of gastric acid secretion and initiation of inflammatory 
cytokines56,57.  
The exact role of microbiota in the origination of gastric cancer is not clear and is poorly 
understood. Using culture-based protocol, a comparatively large number of anaerobic bacteria 
such as Clostridium and Bacteroides was identified in patients with gastric cancer. Elevation of 
the pH in in the gastric lumen due to reduction of acid-secreting cell number may influence 
colonization of microbiota within the gastric mucosa58. Subsequent studies have cast doubts on 
the existence of significant differences in gastric microbiota between control and gastric cancer 
patients, and that the microbiota in gastric cancer patients was dominated by different species of 
the genera Streptococcus, Lactobacillus, Veillonella, and Prevotella57. 
Liver diseases 
Disturbance tothe gut microbiota as a result of extrinsic factors such as unbalanced diet and 
alcohol consumption had been reported to contribute to nonalcoholic fatty liver disease 
(NAFLD), steatohepatitis, alcoholic liver disease, and cirrhosis. Identifying specific microbial 
alterations associated with different liver diseases could improve our understanding of the role of 
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microbiota in the development of liver diseases, and hence could lead to the discovery of novel 
fecal biomarkers.  
Nonalcoholic steatohepatitis (NASH) is characterized by the development of liver inflammation 
and fibrosis. Microbiota samples from NASH patients often yield areduced number of 
Ruminococcaceae and a significantly higher percentage of Clostridium coccoides59. The 
proportion of Bacteroidaceae was lower in samples from alcoholic patients than from 
nonalcoholic individuals60. Aerobic and anaerobic bacterial cultures of jejunal aspirates from 
patients who chronically abuse alcohol were found to be associated with dysbiosis of jejunal 
microflora61.  
At the preclinical level, ethanol intakein rats was associated with dysbiosis, overgrowth of 
bacteria along almost the entire gastrointestinal tract, and significant reductions in proportions of 
probiotic bacteria; Lactobacillus, Pediococcus, Leuconostoc, and Lactococcus62. The use of 
probiotics in patients of alcohol-induced liver injury lead to a marked improvement in liver 
functions63. Modulation of the gut microbiome in response to alcohol intake might be supported 
by various factors including inhibition of intestinal motility, alterations in acid secretion, and 
modulation of the intestinal immune response64,65. 
Extensive research has been devoted to explain the phylogenetic analysis of gut microbiota 
associated with liver cirrhosis66-71.Liver cirrhosis was associated with reduction in the number of 
beneficial bacteria with a concomitant increase of pathogenic microorganisms. Members of the 
Prevotellaceae family have significantly increased in patients with alcoholic cirrhosis compared 
with healthy individual68. Factors contributing to modulation of intestinal microbiome 
includeimpaired motility of the small intestine, reduced bile flow, altered secretion of 
immunoglobulin A, and antimicrobial molecules72. 
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There has been a reciprocal interplay between gut microbiota and liver, where alcohol-induced 
liver diseaseswere reported to impair intestinal barrier by increasing systemic levels of IL1b or 
tumor necrosis factor (TNFα), which disrupt tight junctions73. Increasing intestinal leakage might 
facilitates the movement of microbial products from the lumen of the gut into other distal organs 
including the liver 73. In this respect, reduction of Gram-negative bacteria in the intestine due to 
the use of antibiotics has been associated with decrease in the levels of endotoxins and protection 
against liver disease after ethanol consumption74. 
The dysbiosis of gut microbiota lead to increase in the level of endotoxin and production of 
ammonia which has been implicated in the development of hepatic encephalopathy associated 
with liver cirrhosis75. Interestingly, the number of bacterial species members of 
Enterobacteriaceae including E. coli, Klebsiella, Proteus, and Enterobacter surge in the 
microbiota of patients with cirrhosis67. 
Metabolic disorders 
The gut microbiota plays important rolesin modulatinghost metabolism, extraction of energy 
from ingested food, and synthesis of various metabolites and vitamins.Gut microbiota are also 
essential in the modulation of lipid absorption and deposition, polysaccharide content and the 
production of short-chain fatty acids which have a marked impact on food intake, inflammatory 
tone, or insulin signaling. Recent findings suggested that an altered gut microbial composition 
was associated with metabolic diseases including obesity, diabetes, or non-alcoholic fatty liver 
disease (figure 3)76. 
Changes to the gut microbiota play a critical role in the pathogenesis of obesity and diabetes. In 
humans it has been shown that gut microbiota composition differs between obese and lean 
subjects. Remarkably, inoculation of germ-free (GF) animals with gut microbiota derived from 
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obese controls significantly increase the deposition of fat, and wasassociated with increase in the 
insulin resistance77. Leptin-deficient ob/ob obese mice displayed an alteration in the gut 
microbiota represented by a decrease in Bacteroidetes and a corresponding increase in 
Firmicutes78.    
Recent metagenomics studies showed the presence of reduced numbers of butyrate-producing 
Clostridiales and greater numbers of non-butyrate-producing ones in type 2 diabetes (T2DM), 
suggesting a protective role of butyrate-producing bacteria against T2DM79,80. Furthermore, 
disruption of the gut barrier and microbiota-derived endotoxemia may contribute to the 
pathophysiology of T2DM and obesity. In this regard, modulation of the gut microbiota with 
antibiotics or prebiotics reduces the metabolic endotoximia, decreases inflammatory markers, 
enhances gut permeability, and alleviates glucose intolerance. Moreover, the microbiome 
signature may act as an early diagnostic marker for T2DM, and may provide a novel therapeutic 
target against T2DM and obesity81-83.  
Lately, fecal microbiota transplantation (FMT) was reported to be highly successful therapeutic 
approach for the treatment of recurrent Clostridium difficile infection, a finding that might 
suggest a potential therapeutic protocol for metabolic syndrome84. Inoculation of fecal 
microbiota via gastroduodenal tube from lean donors into obese subjects resulted in an increase 
in the abundance (2.5 fold increase) and diversity of gut microbiota, improvement of insulin 
sensitivity, increase in the proportion of butyrate producer Roseburia intestinalis, and decrease in 
the level of short chain fatty acids85. 
Dysbiotic gut microbiota has been found to play a role in obesity, other obesity related disorders 
such as type 2 diabetes (T2D), and metabolic syndrome86-88.The role ofmicrobiota to weight gain 
and host metabolism is not completely understood. It was suggested that in obese individual, the 
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presence of specific microbial communities may increase the energy harvest and thus predispose 
to obesity86,88.Other studies asserted that there can be several other mechanisms in which the 
microbial populations can influence weight gain and alteration of host metabolism 89. 
Neurodegenerative diseases 
Aging is associated with progressive changes in the gastrointestinal motility, defective gut-blood 
barrier, weakness in the immune function, and improper protein folding. Such age-related 
changes appear to have a great impact on the diversity of gut microbiota and may be linked to the 
age-relatedness of the neurodegenerations90. 
Amyloid protein has been linked to neurodegeneration particularly to Alzheimer’s disease (AD) 
and the possibility of production of amyloid protein by human microbiota might raise great 
concerns about the possible role of microbiota in the induction of AD and other 
neurodegenerative diseases (NDD) including behavioral changes and autism91-95.Nonfunctional 
amyloids is found in yeast and bacteria93. There is paucity of information in literature on the 
potential role of amyloid protein in the pathogenesis of NDD. It was hypothesized that amyloids 
may induce or influence human neurodegeneration by three possible mechanisms including 
misfolding, neruroinflammation, and oxidative stress96.  
Antigen presenting cells such as epithelial microfold (M) cells and dendritic cells may uptake 
proteins produced by gut microbiota and transmit them into neurons in the myenteric plexus 
providing a means of communication between gut microbiota and CNS tissue97. One misfolded 
molecule may elicit the misfolding of a different molecule to cause cross-seeding of Aβ-
aggregation in vitro98 Cross-seeding of neurodegenerative disorder proteins may be induced by 
environmental amyloids such as those produced by bacteria99.  
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Bacterial amyloid has been demonstrated to activate a wide array of inflammatory molecules 
such as toll-like receptor-2 (TLR2), NFκB, TLR1, and CD14100. Cerebral amyloid may mimic 
viral or bacterial infection resulting in glial cell activation through TLRs101. TLR2 activation lead 
to upregulation of Notch1which play a crucial role in the development of AD102. It has been 
established that there is sterile inflammation in the brain in neurodegenerative disorders103.  
Peripheral inflammatory conditions may be involved in the induction of different form of  
neurodegeneration104. It was reported that peripherally-induced inflammation induced damage of 
dopaminergic neurons as a response to the activation of complement pathway of microglial 
cells105. CD14, which is involved in the activation of the TLR2/TLR1 complex lead to 
upregulation of NFκB expression and induction of oxidative toxicity that has been implicated in 
all neurodegenerative disorders106. Bacterial amyloids are recognized through TLR2 mediated 
pathway leading to inflammation and oxidative toxicity that are the main induction factors to AD 
and PD107. 
Conclusion 
Recent advances in metagenomics and metatranscriptomics tools coupled with the availability of 
rapid and cost-effective sequencing platforms have revolutionized the field of microbiome 
research.  However, it remains imperative to completely understand the strengths and limitations 
of current genetic methods used to study the human gut microbiome.Advances in bioinformatics 
and high-throughput sequencing techniques facilitate the identificationof the abundance and 
diversity of human microbiota in the different body niches, andhelp to decipher the possible link 
betweenmicrobiomeand different disease conditions. Such goals are important prerequisites to 
identify novel diagnostic and therapeutic targets that will help to alleviate and cure different 
microbiome-associated diseases. 
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Deciphering the possible inter-individual variations in the microbial composition within different 
body regions and identification ofthe potential role of these human microbiota in the induction of 
different disease conditions is expected to hasten the application of microbiota-driven 
personalized medicine. In addition, it is possible to identifynovel antibiotics againstthe emerging 
antibiotic resistantmicrobiota that may be present in different human body niches. Altogether, 
this comprehensive picture on human microbiome will help understand the current therapeutics 
available for modulating the gut microbiome composition for the prevention and treatment of 
various NCDs and determine whether the dysbiosis and reduced microbial diversity seen in 
many NCDs is causal or a consequence of those diseases. 
Current status of microbiome research discloses the need to map the different types and 
complexity of microbiota among different human populationsglobally and to demonstrate the 
possible reciprocal interplay between some developmental factors, different environmental 
factors such as food, lifestyle, exposure to different environmental hazards and microbiota. 
Research has shown the possible role of microbiota in induction of different disease conditions 
and inexploringpossible noveltherapeutic and preventative strategies to improveand reversethe 
microbiome-associated diseases as well as promote global human health.  
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Figure 3: A diagram showing the microbiota and associated diseases has been added 
 
